Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 19/20 | 0.70 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.58 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.58 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.58 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.58 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.58 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.58 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.58 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.58 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.58 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.58 |
| ▸ | PSMA5 | P28066 | 2/20 | 0.58 |
| ▸ | PSMB4 | P28070 | 2/20 | 0.58 |
| ▸ | PSMB6 | P28072 | 2/20 | 0.58 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.58 |
| ▸ | PSMB3 | P49720 | 2/20 | 0.58 |
| ▸ | PSMA6 | P60900 | 2/20 | 0.58 |
| ▸ | PSMA8 | Q8TAA3 | 2/20 | 0.58 |
| ▸ | PSMB7 | Q99436 | 2/20 | 0.58 |
| ▸ | LONP1 | P36776 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7923798 | 1.00 | PSMB5 (0.70) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL2505810 | 0.96 | PSMB5 (0.73) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL3149386 | 0.83 | PSMB5 (0.72) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL22311178 | 0.83 | PSMB5 (1.00) | PSMB5PSMB1PSMB2 | |
| SCHEMBL3144997 | 0.77 | PSMB5 (0.57) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL3143963 | 0.76 | PSMB5 (0.61) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL3152441 | 0.76 | LONP1 (0.95) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL19381913 | 0.76 | LONP1 (0.95) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL30949467 | 0.75 | PSMB5 (0.66) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL28448228 | 0.75 | PSMB5 (0.66) | PSMB5PSMB1PSMB2PSMB11PSMA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346882-B1 | DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID | MILLENNIUM PHARM INC (US) | 2017-09-20 | — | — | EP | claimed |
| US-10035811-B2 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035811-B2 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170349611-A1 | DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20170349611-A1 | DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-07 | — | — | US | disclosed |
| US-9771381-B2 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771381-B2 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| EP-2346882-B1 | DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID | MILLENNIUM PHARM INC (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-2346882-B1 | DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID | MILLENNIUM PHARM INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20140194387-A1 | DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194387-A1 | DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8664200-B2 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664200-B2 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664200-B2 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20100081633-A1 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081633-A1 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081633-A1 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081633-A1 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | PSMB6, PSMB5, PSMB1 | PSMB5 2/4885PSMB1 3/4885PSMB2 5/4885 |
| US-20140194387-A1 | DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID | PSMB6, PSMB5, PSMB1 | PSMB5 2/4885PSMB1 3/4885PSMB2 5/4885 |
| US-10035811-B2 | Derivatives of 1-amino-2-cyclobutylethylboronic acid | PSMB6, PSMB5, PSMB1 | PSMB5 2/4885PSMB1 3/4885PSMB2 5/4885 |
| US-20170349611-A1 | DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID | PSMB6, PSMB5, PSMB1 | PSMB5 2/4885PSMB1 3/4885PSMB2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.